Real world study on elexacaftor‐tezacaftor‐ivacaftor impact on cholesterol levels in adults with cystic fibrosis

Introduction The introduction of the highly effective modulator therapy elexacaftor‐tezacaftor‐ivacaftor (ETI) has revolutionized the care of persons with cystic fibrosis (PwCF) with major improvements seen in lung function and body mass index. The effects of ETI therapy in real‐world cohorts on oth...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2024-03, Vol.44 (3), p.231-240
Main Authors: Lonabaugh, Kevin, Li, Galvin, List, Rhonda, Huang, Reyna, James, Amber, Barros, Andrew, Somerville, Lindsay, Albon, Dana
Format: Article
Language:English
Subjects:
Adult
Aminophenols
Benzodioxoles
Body mass index
Cholesterol
Cholesterol, LDL
Cystic fibrosis
Cystic Fibrosis - drug therapy
elexacaftor
High density lipoprotein
Humans
Indoles
ivacaftor
Low density lipoprotein
Multivariate analysis
Mutation
Pyrazoles
Pyridines
Pyrrolidines
Quinolones
Respiratory function
Retrospective Studies
Risk factors
Statistical analysis
tezacaftor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The introduction of the highly effective modulator therapy elexacaftor‐tezacaftor‐ivacaftor (ETI) has revolutionized the care of persons with cystic fibrosis (PwCF) with major improvements seen in lung function and body mass index. The effects of ETI therapy in real‐world cohorts on other parameters such as cholesterol levels are largely unknown. Methods A single‐center, retrospective chart review study was conducted to assess the change in lipid panels before and after ETI initiation. The study investigated total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), and triglyceride levels using both a univariate and multivariate mixed‐effects model to evaluate the change after initiation of ETI in a cohort of PwCF. Results There were 128 adult PwCF included in the analysis. Statistically significant changes were seen in both univariate and multivariate analyses for TC, LDL‐C, and HDL‐C. On multivariate analysis, TC increased by an average of 15.0 mg/dL after ETI initiation (p 
ISSN:0277-0008
1875-9114
DOI:10.1002/phar.2903